Cargando…
Rituximab Prevents Stroke Recurrences in Atypical Chronic Immune-Mediated Thrombotic Thrombocytopenic Purpura
Autores principales: | Dupuy, Henry, Lazaro, Estibaliz, Machelart, Irène, Viallard, Jean-François, Coppo, Paul, Rivière, Etienne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524916/ https://www.ncbi.nlm.nih.gov/pubmed/31249968 http://dx.doi.org/10.1055/s-0038-1676357 |
Ejemplares similares
-
Atypical Thrombotic Thrombocytopenic Purpura Presenting as Stroke
por: Badugu, Pradeepthi, et al.
Publicado: (2019) -
Thrombotic thrombocytopenic purpura treated with rituximab in systemic lupus erythematosus
por: Karimifar, Mansoor
Publicado: (2012) -
Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura
por: Chen, Haifei, et al.
Publicado: (2017) -
Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine
por: Coppo, Paul, et al.
Publicado: (2018) -
Thrombotic thrombocytopenic purpura
por: Knöbl, Paul
Publicado: (2018)